3 / 6
Note:
Hematology and Blood Disorders | Volume 2
Page 25
July 25-26, 2019 | Amsterdam, Netherlands
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
Global Hematology 2019
4
th
International Conference on
HEMATOLOGY AND
BONE MARROW TRANSPLANTATION
IMPACT OF BLOOD TRANSFUSION ON HEMATOPOIETIC STEM CELL TRANSPLANTATION
OUTCOME
Nermeen A Nabih, Shaza Abdel Wahab, Rasha Magdy
and
Gehan Kamal
Ain Shams University, Egypt
Background:
Allogeneic hematopoietic stem cell transplantation (AHSCT) is a potentially curative therapy for
many malignant and non-malignant disorders.
Objectives:
The aim of author’s single centre retrospective study was to investigate the impact of blood trans-
fusion on the outcome of AHSCT.
Patients &Methods:
A total of 50 adults patients with haematological malignancies received allogeneic bone
marrow transplantation were analysed, regarding the incidence of infection‚ acute and chronic GvHD and over-
all survival, for three months before to one year after AHSCT. The patients were divided into two groups accord-
ing to the amount of transfused RBCS and platelets units. The low transfusion group (<10 units, n=30) and high
transfusion group (>10unites, n=20).
Results:
The incidence of infectious episodes and GvHD development were significantly higher among the
high transfusion group than that in low transfusion group (p=0.006) and (p=0.02) respectively. In the low trans-
fusion group the incidence of a GvHD was 3.3% and of the chronic GvHD was 3.3% while in high transfusion
group the incidence of a GvHD was 15% and of chronic GvHD was 20%. Regarding the overall survival though
during the first year the overall survival was significantly lower in the high transfusion group 25% than that in
the low transfusion group 46.7% (p=0.02) however the difference between the two groups was not significant
(p=0.09) during the median survival time (Two years).
Conclusion:
These data indicate that higher transfusion history was associated with increased risk of infection,
development of GvHD and worse overall survival in patients received AHSCT, thus new rational for improving
transfusion practice for such patients is warranted based on symptoms driven criteria.
Hematol Blood Disord 2019, Volume 2